Register Login

AVALO THERAPEUTICS, INC. (AVTX)

Sullivan Christopher Ryan 🟡 adjusted position in 72.7K shares (3 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.05 ($2.9M) Transaction Date: Aug 17, 2026 | Filing ID: 000019

Full text
Register to leave comments
  • News bot Aug. 19, 2026, 8:11 p.m.

    🔍 Sullivan Christopher Ryan (Executive)

    Company: Avalo Therapeutics, Inc. (AVTX)

    Report Date: 2026-08-17

    Transaction Summary:

    • Total transactions: 9
    • Derivative instruments: 3
    • Holdings reported: 0
    • Total shares acquired: 71,852
    • Total shares sold: 144,577

    Detailed Transactions and Holdings:

    • Acquired 37,945 shares of Common Stock at $9.88 per share (Direct)
      Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 78,718.00 | transaction_form_type: 4 | Footnotes: F1
    • Acquired 2,876 shares of Common Stock at $9.88 per share (Direct)
      Date: 2026-08-17 | Code: M | equity_swap_involved: 0 | shares_owned_after: 81,594.00 | transaction_form_type: 4
    • Sold 37,945 shares of Common Stock at $19.8533 per share (Direct)
      Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 43,649.00 | transaction_form_type: 4 | Footnotes: F1, F2
    • Sold 3,749 shares of Common Stock at $19.9419 per share (Direct)
      Date: 2026-08-17 | Code: S | equity_swap_involved: 0 | shares_owned_after: 39,900.00 | transaction_form_type: 4 | Footnotes: F3
    • Acquired 31,031 shares of Common Stock at $9.88 per share (Direct)
      Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 70,931.00 | transaction_form_type: 4
    • Sold 31,031 shares of Common Stock at $20.0549 per share (Direct)
      Date: 2026-08-18 | Code: S | equity_swap_involved: 0 | shares_owned_after: 39,900.00 | transaction_form_type: 4 | Footnotes: F4
    • Sold 37,945 shares of Stock Option (Right to Buy) at $9.88 per share (Derivative)
      Date: 2026-08-17 | Code: M | Expires: 2034-08-13 | equity_swap_involved: 0 | shares_owned_after: 130,149.00 | transaction_form_type: 4 | Footnotes: F1, F5
    • Sold 2,876 shares of Stock Option (Right to Buy) at $9.88 per share (Derivative)
      Date: 2026-08-17 | Code: M | Expires: 2034-08-13 | equity_swap_involved: 0 | shares_owned_after: 127,273.00 | transaction_form_type: 4 | Footnotes: F5
    • Sold 31,031 shares of Stock Option (Right to Buy) at $9.88 per share (Derivative)
      Date: 2026-08-18 | Code: M | Expires: 2034-08-13 | equity_swap_involved: 0 | shares_owned_after: 96,242.00 | transaction_form_type: 4 | Footnotes: F5

    Footnotes:

    • F1: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
    • F2: The reported securities were sold in multiple transactions at prices ranging from $19.16 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
    • F3: The reported securities were sold in multiple transactions at prices ranging from $19.70 to $20.02. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
    • F4: The reported securities were sold in multiple transactions at prices ranging from $20.00 to $20.265. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
    • F5: The stock option vests 25% on March 28, 2025, and 1/36 monthly thereafter, subject to the Reporting Person's continued service on such vesting date.

Search

News categories